Aussie Chemgenex Licenses Leukemia Drug To Support U.S. Push
This article was originally published in PharmAsia News
Executive Summary
Australia's Chemgenex has signed a deal with U.S.-based Hospira that could be worth $119.4 million to the Australian firm by the time it runs its course
You may also be interested in...
Hospira To Acquire Injectable Drug Business Of India's Orchid Pharmaceuticals
WASHINGTON - Hospira announced Dec. 15 it will purchase Orchid Chemicals & Pharmaceuticals' generic injectable drug business for $400 million, thereby filling one gap in the company's broadening therapeutic coverage
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.